INS and type 2 diabetes mellitus: The All to Target study in Type 2 diabetes was a 60-week, randomized, open-label study that compared (1) insulin glargine plus one injection of insulin glulisine, (2) insulin glargine plus up to three injections of insulin glulisine and (3) two injections of premixed insulin (biphasic insulin aspart 70/30) 43.